These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 8839853

  • 1. Recombinant human factor IX: replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B.
    Brinkhous KM, Sigman JL, Read MS, Stewart PF, McCarthy KP, Timony GA, Leppanen SD, Rup BJ, Keith JC, Garzone PD, Schaub RG.
    Blood; 1996 Oct 01; 88(7):2603-10. PubMed ID: 8839853
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetic and pharmacodynamic properties of plasma-derived vs. recombinant factor IX in patients with hemophilia B: a prospective crossover study.
    Alamelu J, Bevan D, Sorensen B, Rangarajan S.
    J Thromb Haemost; 2014 Dec 01; 12(12):2044-8. PubMed ID: 25315324
    [Abstract] [Full Text] [Related]

  • 3. Prolonged activity of factor IX as a monomeric Fc fusion protein.
    Peters RT, Low SC, Kamphaus GD, Dumont JA, Amari JV, Lu Q, Zarbis-Papastoitsis G, Reidy TJ, Merricks EP, Nichols TC, Bitonti AJ.
    Blood; 2010 Mar 11; 115(10):2057-64. PubMed ID: 20056791
    [Abstract] [Full Text] [Related]

  • 4. A commentary on the differences in pharmacokinetics between recombinant and plasma-derived factor IX and their implications for dosing.
    Björkman S.
    Haemophilia; 2011 Mar 11; 17(2):179-84. PubMed ID: 21299739
    [Abstract] [Full Text] [Related]

  • 5. Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX.
    Collins PW, Møss J, Knobe K, Groth A, Colberg T, Watson E.
    J Thromb Haemost; 2012 Nov 11; 10(11):2305-12. PubMed ID: 22998153
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics of plasma-derived and recombinant factor IX - implications for prophylaxis and on-demand therapy.
    Björkman S.
    Haemophilia; 2013 Nov 11; 19(6):808-13. PubMed ID: 23786333
    [Abstract] [Full Text] [Related]

  • 7. Recombinant FIX Fc fusion protein activity assessment with the one-stage clotting assay: A multicenter, assessor-blinded, prospective study in Japan (J-Field Study).
    Fukutake K, Kobayashi T, Sommer JM, Hirakata T.
    Int J Lab Hematol; 2020 Apr 11; 42(2):162-169. PubMed ID: 31820573
    [Abstract] [Full Text] [Related]

  • 8. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates.
    Roth DA, Kessler CM, Pasi KJ, Rup B, Courter SG, Tubridy KL, Recombinant Factor IX Study Group.
    Blood; 2001 Dec 15; 98(13):3600-6. PubMed ID: 11739163
    [Abstract] [Full Text] [Related]

  • 9. Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgery.
    Preijers T, Hazendonk HCAM, Liesner R, Chowdary P, Driessens MHE, Hart D, Keeling D, Laros-van Gorkom BAP, van der Meer FJM, Meijer K, Fijnvandraat K, Leebeek FWG, Collins PW, Cnossen MH, Mathôt RAA, OPTI‐CLOT study group.
    J Thromb Haemost; 2018 Nov 15; 16(11):2196-2207. PubMed ID: 30394056
    [Abstract] [Full Text] [Related]

  • 10. Improved kinetics of rIX-FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and hemophilia B dogs.
    Nolte MW, Nichols TC, Mueller-Cohrs J, Merricks EP, Pragst I, Zollner S, Dickneite G.
    J Thromb Haemost; 2012 Aug 15; 10(8):1591-9. PubMed ID: 22726310
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics of recombinant factor IX after intravenous and subcutaneous administration in dogs and cynomolgus monkeys.
    McCarthy K, Stewart P, Sigman J, Read M, Keith JC, Brinkhous KM, Nichols TC, Schaub RG.
    Thromb Haemost; 2002 May 15; 87(5):824-30. PubMed ID: 12038784
    [Abstract] [Full Text] [Related]

  • 12. Recombinant factor IX: discrepancies between one-stage clotting and chromogenic assays.
    Wilmot HV, Hogwood J, Gray E.
    Haemophilia; 2014 Nov 15; 20(6):891-7. PubMed ID: 24800651
    [Abstract] [Full Text] [Related]

  • 13. In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates.
    Preijers T, Bukkems L, van Spengler M, Leebeek F, Cnossen M, Mathôt R.
    Eur J Clin Pharmacol; 2021 Aug 15; 77(8):1193-1200. PubMed ID: 33624121
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Measuring factor IX activity of nonacog beta pegol with commercially available one-stage clotting and chromogenic assay kits: a two-center study.
    Bowyer AE, Hillarp A, Ezban M, Persson P, Kitchen S.
    J Thromb Haemost; 2016 Jul 15; 14(7):1428-35. PubMed ID: 27107268
    [Abstract] [Full Text] [Related]

  • 16. Factor IX replacement to cover total knee replacement surgery in haemophilia B: a single-centre experience, 2000-2010.
    Uprichard J, Adamidou D, Goddard NJ, Mann HA, Yee TT.
    Haemophilia; 2012 Jan 15; 18(1):46-9. PubMed ID: 21545378
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Monitoring once-weekly recombinant factor IX prophylaxis in hemophilia B with thrombin generation assay and factor IX activity.
    Nummi V, Jouppila A, Lassila R.
    Int J Lab Hematol; 2017 Aug 15; 39(4):359-368. PubMed ID: 28406575
    [Abstract] [Full Text] [Related]

  • 19. A retrospective study to describe the incidence of moderate to severe allergic reactions to factor IX in subjects with haemophilia B.
    Recht M, Pollmann H, Tagliaferri A, Musso R, Janco R, Neuman WR.
    Haemophilia; 2011 May 15; 17(3):494-9. PubMed ID: 21518148
    [Abstract] [Full Text] [Related]

  • 20. Pharmacokinetic study of recombinant human factor IX in previously treated patients with hemophilia B in Taiwan.
    Chang HH, Yang YL, Hung MH, Tsay W, Shen MC.
    J Formos Med Assoc; 2007 Apr 15; 106(4):281-7. PubMed ID: 17475604
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.